Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma

References

• Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34(6):877–885. doi:10.1002/hed.2183022127982
   PubMed Web of Science ®Google Scholar
• Jegoux F, Metreau A, Louvel G, Bedfert C. Paranasal sinus cancer. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(6):327–335. doi:10.1016/j.anorl.2012.07.00723523040
   PubMed Web of Science ®Google Scholar
• Lopez F, Lund VJ, Suarez C, et al. The impact of histologic phenotype in the treatment of sinonasal cancer. Adv Ther. 2017;34(10):2181–2198. doi:10.1007/s12325-017-0605-928871554
   PubMed Web of Science ®Google Scholar
• Robin TP, Jones BL, Gordon OM, et al. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer-Am Cancer Soc. 2017;123(16):3040–3049.
   Google Scholar
• Vazquez A, Khan MN, Blake DM, Patel TD, Baredes S, Eloy JA. Sinonasal squamous cell carcinoma and the prognostic implications of its histologic variants: a population-based study. Int Forum Allergy Rhinol. 2015;5(1):85–91. doi:10.1002/alr.2141825278180
   PubMed Web of Science ®Google Scholar
• Dubal PM, Bhojwani A, Patel TD, et al. Squamous cell carcinoma of the maxillary sinus: a population-based analysis. Laryngoscope. 2016;126(2):399–404. doi:10.1002/lary.2560126393540
   PubMed Web of Science ®Google Scholar
• Kang JH, Cho SH, Kim JP, et al. Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis. J Oral Maxillofac Surg. 2012;70(7):1717–1723. doi:10.1016/j.joms.2011.06.22121945430
   PubMed Web of Science ®Google Scholar
• Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261. doi:10.21037/atm.2016.04.0527563648
   PubMed Web of Science ®Google Scholar
• Moskovitz J, Moy J, Ferris RL. Immunotherapy for head and neck squamous cell carcinoma. Curr Oncol Rep. 2018;20(2):22. doi:10.1007/s11912-018-0654-529502288
   PubMed Web of Science ®Google Scholar
• Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P. Immuno-oncology in head and neck squamous cell cancers: news from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev. 2018;65:78–86. doi:10.1016/j.ctrv.2018.03.00329574334
   PubMed Web of Science ®Google Scholar
• Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41(10):868–876. doi:10.1016/j.ctrv.2015.11.00126589760
   PubMed Web of Science ®Google Scholar
• Sano D, Oridate N. The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol. 2016;21(5):819–826. doi:10.1007/s10147-016-1005-x27339270
   PubMed Web of Science ®Google Scholar
• Smith EM, Wang D, Kim Y, et al. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol. 2008;44(2):133–142. doi:10.1016/j.oraloncology.2007.01.01017360226
   PubMed Web of Science ®Google Scholar
• Chung CH, Zhang Q, Kong CS, et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of non-oropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014;32(35):3930–3938. doi:10.1200/JCO.2013.54.522825267748
   PubMed Web of Science ®Google Scholar
• Chen SC, Chang PM, Wang HJ, Tai SK, Chu PY, Yang MH. PD-L1 expression is associated with p16(INK4A) expression in non-oropharyngeal head and neck squamous cell carcinoma. Oncol Lett. 2018;15(2):2259–2265. doi:10.3892/ol.2017.756429434933
   PubMed Web of Science ®Google Scholar
• Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–1741. doi:10.1158/0008-5472.CAN-12-238423288508
   PubMed Web of Science ®Google Scholar
• Ryu HJ, Kim EK, Heo SJ, Cho BC, Kim HR, Yoon SO. Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma. Apmis. 2017;125(11):974–984. doi:10.1111/apm.1274428975663
   PubMed Web of Science ®Google Scholar
• Castaneda CA, Castillo M, Torres-Cabala C, et al. Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. Clin Transl Oncol. 2019. doi:10.1007/s12094-019-02033-x
   PubMed Web of Science ®Google Scholar
• Riobello C, Vivanco B, Reda S, et al. Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. Head Neck. 2018;40(4):818–827. doi:10.1002/hed.2506729356178
   PubMed Web of Science ®Google Scholar
• Straub M, Drecoll E, Pfarr N, et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget. 2016;7(11):12024–12034. doi:10.18632/oncotarget.759326918453
   PubMedGoogle Scholar
• An HJ, Ko GH, Lee JH, et al. programmed death-ligand 1 expression and its correlation with lymph node metastasis in papillary thyroid carcinoma. J Pathol Transl Med. 2018;52(1):9–13. doi:10.4132/jptm.2017.07.2628994272
   PubMed Web of Science ®Google Scholar
• Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One. 2015;10(6):e131403.
   PubMed Web of Science ®Google Scholar
• Lee VH, Lo AW, Leung CY, et al. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. PLoS One. 2016;11(6):e157969.
   Web of Science ®Google Scholar
• Fiedler M, Weber F, Hautmann MG, et al. Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. Clin Oral Investig. 2018;22(1):189–200. doi:10.1007/s00784-017-2099-x
   PubMed Web of Science ®Google Scholar
• Fukushima Y, Someya M, Nakata K, et al. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. Radiother Oncol. 2018;129(2):409–414. doi:10.1016/j.radonc.2018.08.02330249348
   PubMed Web of Science ®Google Scholar
• Badalamenti G, Fanale D, Incorvaia L, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol. 2018. doi:10.1016/j.cellimm.2018.01.013
   PubMed Web of Science ®Google Scholar
• De Meulenaere A, Vermassen T, Aspeslagh S, Vandecasteele K, Rottey S, Ferdinande L. TILs in head and neck cancer: ready for clinical implementation and why (not)? Head Neck Pathol. 2017;11(3):354–363. doi:10.1007/s12105-016-0776-828032290
   PubMedGoogle Scholar
• Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117(4):451–460. doi:10.1038/bjc.2017.22028704840
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179. doi:10.1038/srep1517926462617
   PubMed Web of Science ®Google Scholar
• Cancer: MA. Inflaming metastasis. Nature. 2009;457(7225):36–37. doi:10.1038/457036b19122629
   PubMed Web of Science ®Google Scholar
• Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010;28(27):4142–4148. doi:10.1200/JCO.2010.29.290420697079
   PubMed Web of Science ®Google Scholar
• Belobrov S, Cornall AM, Young RJ, et al. The role of human papillomavirus in p16-positive oral cancers. J Oral Pathol Med. 2018;47(1):18–24. doi:10.1111/jop.1264929024035
   PubMed Web of Science ®Google Scholar
• Ilardi G, Russo D, Varricchio S, et al. HPV virus transcriptional status assessment in a case of sinonasal carcinoma. Int J Mol Sci. 2018;19(3):883. doi:10.3390/ijms19030883
   PubMed Web of Science ®Google Scholar
• Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. 2016;22(3):704–713. doi:10.1158/1078-0432.CCR-15-154326408403
   PubMed Web of Science ®Google Scholar
• Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47(12):1148–1153. doi:10.1016/j.oraloncology.2011.08.00721911310
   PubMed Web of Science ®Google Scholar
• Concha-Benavente F, Srivastava RM, Trivedi S, et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFN-gamma that induce PD-L1 expression in head and neck cancer. Cancer Res. 2016;76(5):1031–1043. doi:10.1158/0008-5472.CAN-15-200126676749
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–2145. doi:10.1158/0008-5472.CAN-15-025525977340
   PubMed Web of Science ®Google Scholar
• Azuma K, Ota K, Kawahara A, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer. Ann Oncol. 2014;25(10):1935–1940. doi:10.1093/annonc/mdu24225009014
   PubMed Web of Science ®Google Scholar